Literature DB >> 21162652

Stimulation of anti-tumor immunity by photodynamic therapy.

Pawel Mroz1, Javad T Hashmi, Ying-Ying Huang, Norbert Lange, Michael R Hamblin.   

Abstract

Photodynamic therapy (PDT) is a rapidly developing cancer treatment that utilizes the combination of nontoxic dyes and harmless visible light to destroy tumors by generating reactive oxygen species. PDT produces tumor-cell destruction in the context of acute inflammation that acts as a 'danger signal' to the innate immune system. Activation of the innate immune system increases the priming of tumor-specific T lymphocytes that have the ability to recognize and destroy distant tumor cells and, in addition, lead to the development of an immune memory that can combat recurrence of the cancer at a later point in time. PDT may be also successfully combined with immunomodulating strategies that are capable of overcoming or bypassing the escape mechanisms employed by the progressing tumor to evade immune attack. This article will cover the role of the immune response in PDT anti-tumor effectiveness. It will highlight the milestones in the development of PDT-mediated anti-tumor immunity and emphasize the combination strategies that may improve this therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162652      PMCID: PMC3060712          DOI: 10.1586/eci.10.81

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  156 in total

1.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

Authors:  Seung-Yong Seong; Polly Matzinger
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

2.  ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Susan E Bates
Journal:  Cancer Biol Ther       Date:  2005-02-08       Impact factor: 4.742

3.  Photodynamic therapy-generated vaccine for cancer therapy.

Authors:  Mladen Korbelik; Jinghai Sun
Journal:  Cancer Immunol Immunother       Date:  2005-10-08       Impact factor: 6.968

4.  Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Authors:  Laurence Zitvogel; Oliver Kepp; Laura Senovilla; Laurie Menger; Nathalie Chaput; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2010-04-26       Impact factor: 12.531

5.  Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo.

Authors:  W J de Vree; M C Essers; H S de Bruijn; W M Star; J F Koster; W Sluiter
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

6.  Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages.

Authors:  S Evans; W Matthews; R Perry; D Fraker; J Norton; H I Pass
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

7.  Acute phase response induction by cancer treatment with photodynamic therapy.

Authors:  Mladen Korbelik; Ivana Cecic; Soroush Merchant; Jinghai Sun
Journal:  Int J Cancer       Date:  2008-03-15       Impact factor: 7.396

8.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

9.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  76 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils.

Authors:  Masamitsu Tanaka; Manabu Kinoshita; Yasuo Yoshihara; Nariyoshi Shinomiya; Shuhji Seki; Koichi Nemoto; Takahiro Hirayama; Tianhong Dai; Liyi Huang; Michael R Hamblin; Yuji Morimoto
Journal:  Photochem Photobiol       Date:  2011-10-31       Impact factor: 3.421

Review 3.  Intraoperative adjuncts for malignant pleural mesothelioma.

Authors:  Warren Ho Chan; David J Sugarbaker; Bryan M Burt
Journal:  Transl Lung Cancer Res       Date:  2017-06

4.  Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg
Journal:  Ann Cardiothorac Surg       Date:  2012-11

5.  Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment.

Authors:  Jayoung Kim
Journal:  Transl Androl Urol       Date:  2019-07

6.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

Review 7.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

8.  5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

Authors:  Malgorzata Wachowska; Magdalena Gabrysiak; Angelika Muchowicz; Weronika Bednarek; Joanna Barankiewicz; Tomasz Rygiel; Louis Boon; Pawel Mroz; Michael R Hamblin; Jakub Golab
Journal:  Eur J Cancer       Date:  2014-02-18       Impact factor: 9.162

9.  Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle.

Authors:  María García-Díaz; Masayoshi Kawakubo; Pawel Mroz; M Lluïsa Sagristà; Margarita Mora; Santi Nonell; Michael R Hamblin
Journal:  J Control Release       Date:  2012-07-27       Impact factor: 9.776

10.  Photodynamic Therapy for Cancer and for Infections: What Is the Difference?

Authors:  Sulbha K Sharma; Pawel Mroz; Tianhong Dai; Ying-Ying Huang; Tyler G St Denis; Michael R Hamblin
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.